Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 9/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.34 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3947048 | 0.88 | TGFBR1 (0.53) | TGFBR1S1PR4GRM5PDGFRBPDGFRA | |
| SCHEMBL3943494 | 0.85 | S1PR4 (0.48) | TGFBR1S1PR4GRM5SMARCA2SMARCA4 | |
| SCHEMBL22186851 | 0.85 | S1PR4 (0.51) | TGFBR1S1PR4SMARCA2SMARCA4 | |
| SCHEMBL22186856 | 0.81 | TGFBR1 (0.55) | TGFBR1S1PR4GRM5 | |
| SCHEMBL22186414 | 0.81 | TGFBR1 (0.38) | TGFBR1S1PR4GRM5 | |
| SCHEMBL22186823 | 0.80 | SYK (0.41) | TGFBR1GRM5 | |
| SCHEMBL3950789 | 0.80 | SYK (0.49) | TGFBR1SCN9A | |
| SCHEMBL22850819 | 0.80 | TGFBR1 (0.57) | TGFBR1S1PR4 | |
| SCHEMBL22186828 | 0.80 | SYK (0.44) | TGFBR1S1PR4SCN5ASCN9A | |
| SCHEMBL22187103 | 0.80 | SYK (0.46) | TGFBR1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| WO-2009022171-A1 | PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048269-A1 | CHEMICAL COMPOUNDS-821 | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885S1PR4 549/4885GRM5 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.